Sanofi Consumer Healthcare India Limited has announced the appointment of Mr. Narahari Naidu as its new Chief Financial Officer, effective August 4th, 2025. This strategic move comes as the company reports robust financial results for the second quarter of 2025.

New CFO Appointment

The Board of Directors, based on recommendations from the Nomination and Remuneration Committee and in consultation with the Audit Committee, has approved Mr. Naidu's appointment for a six-month term. Mr. Naidu brings over 14 years of diverse experience across healthcare/pharmaceuticals, manufacturing, and consulting sectors. His expertise spans:

• Finance & Accounts
• Procurement
• Investor Relations
• Mergers & Acquisitions
• Banking & Treasury
• IPO management

Prior to joining Sanofi Consumer Healthcare India, he served as Group CFO for entities operating across India, UK, and USA.

Strong Q2 Financial Performance

Alongside this key appointment, Sanofi Consumer Healthcare India has reported impressive financial results for the quarter ended June 30, 2025:

• Revenue from Operations: The company achieved a revenue of ₹2,209.00 million, marking a significant 28.21% year-on-year growth from ₹1,723.00 million in the same quarter last year.

• Profit After Tax: Net profit rose to ₹607.00 million, a 21.40% increase compared to ₹500.00 million in the previous quarter and a substantial 109.31% jump from ₹290.00 million in Q2 2024.

• Earnings Per Share: The Basic and Diluted EPS stood at ₹26.36, up from ₹21.69 in the previous quarter and ₹12.58 in Q2 2024.

Financial Highlights

Product Relaunch and Exceptional Items

The company has successfully relaunched Depura Adult and Combiflam Suspension during the recent quarters, following a voluntary recall in the previous year. This strategic move has contributed to the strong performance in Q2 2025.

Additionally, Sanofi Consumer Healthcare India recorded an exceptional gain of ₹66.00 million in Q2 2025 from reversing excess demerger-related provisions made in the previous year.

Outlook

With the appointment of Mr. Narahari Naidu as CFO and the strong financial performance in Q2 2025, Sanofi Consumer Healthcare India appears well-positioned for continued growth. The company's focus on relaunching key products and optimizing its financial structure suggests a strategic approach to enhancing shareholder value and market presence in the competitive pharmaceutical sector.

Investors and industry observers will be keenly watching how Mr. Naidu's extensive experience will contribute to Sanofi Consumer Healthcare India's financial strategies and growth initiatives in the coming months.

Sanofi Consumer Healthcare India Limited has reported robust financial results for the first quarter, demonstrating significant growth in both revenue and profitability.

Revenue Surge

The company's revenue from operations for Q1 stood at ₹2,209.00 million, marking a substantial 28% increase from ₹1,723.00 million in the same quarter of the previous year. This impressive growth reflects the company's strong market position and successful product strategies.

Profit Boost

Net profit for the quarter rose by 109% to ₹607.00 million, compared to ₹290.00 million in Q1 of the previous year. This notable increase in profitability underscores the company's effective cost management and operational efficiency.

Financial Highlights

Operational Performance

The company's total income for Q1 reached ₹2,265.00 million, a 31% increase from ₹1,731.00 million in the corresponding quarter of the previous year. This growth was primarily driven by strong sales performance and an increase in other income.

Product Relaunch and Future Outlook

Sanofi Consumer Healthcare India successfully relaunched Combiflam Suspension during the quarter, following the relaunch of Depura Adult in the previous quarter. The company continues its efforts to bring back other recalled products to the market, which is expected to further boost its performance in the coming quarters.

Exceptional Items

The company recorded an exceptional gain of ₹66.00 million in Q1 from reversing excess demerger-related provisions made in the previous year, contributing to the overall profit growth.

Management Changes

In a separate announcement, the company's Board of Directors approved the appointment of Mr. Narahari Naidu as the Chief Financial Officer, effective August 4. Mr. Naidu brings over 14 years of diverse experience across various organizations in the healthcare, pharmaceuticals, manufacturing, and consulting sectors.

Sanofi Consumer Healthcare India's strong Q1 results demonstrate its resilience and growth potential in the competitive pharmaceutical market. The company's focus on product relaunches and strategic management appointments positions it well for continued success in the coming quarters.